Drug Profile
NP 000888
Alternative Names: NP-000888Latest Information Update: 21 Oct 2020
Price :
$50
*
At a glance
- Originator Galderma
- Class Antipsoriatics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 21 Oct 2020 No development reported - Phase-II for Psoriasis in Taiwan (Topical) (NCT02995473)
- 12 Jun 2018 Galderma completes a phase II trial in Psoriasis in Taiwan (NCT02995473)
- 08 Feb 2017 Phase-II clinical trials in Psoriasis in Taiwan (Topical) (NCT02995473)